longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)															
Name and Address of Reporting Person Lin Patrick				2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]							5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106			3. Date of Earliest Transaction (Month/Day/Year) 04/01/2022							X_ Officer (giv		Other	y Off			
(Street) HANOVER, MD 21076				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City)	(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu							ies Acquire	nired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			(Instr. 8)		(A) or Disposed (Instr. 3, 4 and 5) V Amount (D)		of (D) Owned Follow Transaction(s) (Instr. 3 and 4				Ownership Form: I Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Table II -					red, Dis	posed	of, or Ben						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g., puts, call 4. if Transaction Code r) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of		and Expiration Date (Month/Day/Year) of Und Securit (Instr.		rities)	and Amount 8. Price of Derivative Security		9. Number of Derivative Securities Beneficially Owned	Form of Derivative Security:	(Instr. 4)	
	Security					(D) (Instr. 3, 4, and 5)		, I					Following Reported Transaction(s)			
				Code	V	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Restricted Stock Units	\$ 0	04/01/2022		A		247,841		<u>(1</u>	ŋ	(1)	Common Stock	247,841	\$ 0	302,766) D	
Report	ing Ov	vners										7				

	Relationships						
Reporting Owner Name / Address	Director	Director 0wner Officer		Other			
Lin Patrick C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Business - Strategy Off				

Signatures

/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact	04/11/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.
- (2) The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.